Clicky

Diffusion Pharmaceuticals Inc.(DFFN)

Description: Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.


Keywords: Medicine Biotechnology Cancer Oncology Radiation Cancer Treatment Chemotherapy Ophthalmology Clinical Development Dermatology Radiation Therapy Macular Degeneration Glioblastoma Acne Oxygen Blastoma Brain Tumor Cancer Cell Signal Transduction Glioblastoma Multiforme Acne Vulgaris mTOR Oncology Applications Pi3k/Akt/Mtor Pathway

Home Page: www.diffusionpharma.com

DFFN Technical Analysis

300 East Main Street
Charlottesville, VA 22902
United States
Phone: 434 220 0718


Officers

Name Title
Dr. Robert J. Cobuzzi Jr., Ph.D. Pres, CEO & Director
Mr. William Karl Hornung Chief Financial Officer
Mr. William Robert Elder J.D. Gen. Counsel & Corp. Sec.
Dr. Christopher D. Galloway M.D. Chief Medical Officer
Dr. David Randolph Jones M.D. Sr. Medical Advisor
Ms. Suzanne Cassidy Sr. Director & Head of Quality Assurance
Dr. Jennifer Llewelyn Ph.D. Sr. Director & Head of CMC
Ms. Raven Jaeger M.S. Chief Regulatory Officer
Ms. Kelly Hoy Director of Project Management
Mr. Harry Cook VP of Clinical Operations

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.5113
Price-to-Sales TTM: 0
IPO Date: 2016-01-04
Fiscal Year End: December
Full Time Employees: 16
Back to stocks